▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #169 by analyst upside · 2026-11-13
TARA
Protara Therapeutics, Inc.
Healthcare · Market Cap $150M · P/E 0x
ANALYST PRICE TARGET
+938.3%
implied upside to consensus target
Current Price $2.44
Consensus Target $25.33
Bull Target $30.0
Bear Target $18.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
0
Sell
0
52-Week Low $2.09
52-Week High $7.82
YTD Return -54.6%
FUNDAMENTALS
Market Cap $150M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.39
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.09
52-Week High $7.82
Current Price $2.44
Bear Target $18.0
Bull Target $30.0
● Now $2.44 ● Target $25.33
TRADING DATA
Avg Volume 1.0M
YTD Return -54.6%
Analyst Count 6
Consensus Buy
Upside to Target +938.3%
Last Updated 2026-11-13

ANALYST SUMMARY

Protara Therapeutics, Inc. (TARA) is currently trading at $2.44 with a Wall Street consensus price target of $25.33, implying potential upside of 938.3% over the next 12 months. 6 analysts currently cover TARA, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $18.0.

TARA operates in the Healthcare sector with a market capitalisation of $150M. The stock is down 54.6% year-to-date and is currently trading near the lower end of its 52-week range of $2.09 – $7.82.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TARA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Oppenheimer - Reiterated
Outperform → Outperform 2026-05-20 14% win rate (7 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-05-14 43% win rate (7 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-04-29 31% win rate (48 calls)
JP Morgan ● Initiated
Overweight 2026-03-04 43% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-02-10 31% win rate (48 calls)
Piper Sandler ● Initiated
Overweight 2026-01-07 14% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-12-03 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-11-19 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
42
out of 100
Coverage depth
15/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →